Chromium Picolinate and Biotin Lower Heart Disease Risk for Type
Francisco CA, 6 May 2004
Source: Nutrition 21, Inc.
of a new double-blind, placebo-controlled, randomized clinical study
show that daily nutritional supplementation with a combination of
chromium picolinate and biotin (marketed as Diachrome) significantly
improved coronary risk factors in people with type 2 diabetes.
clinical study, which evaluated 24 patients over 30 days, was presented
today at the AHA's Annual Conference on Arteriosclerosis, Thrombosis
& Vascular Biology (ATVB) in San Francisco.
study found the following significant improvements in subjects who
added Diachrome to their treatment regimen:
cholesterol levels dropped an average of 19.1 mg/dL
("bad") cholesterol levels dropped an average of 10.9 mg/dL
fasting blood glucose (FBG) levels decreased 26.2 mg/dL
dropped -5.3 mg/dl
of apo-B/apo-A; LDL-C/HDL-C improved
study emphasizes that Diachrome not only improves blood sugar
levels, but decreases LDL cholesterol which will help people with
diabetes meet the ATP III guidelines for cholesterol which is difficult
for them to achieve, " states Jeffrey Geohas, MD, principal investigator,
medical director, Radiant Research, Chicago. "Diachrome should be
considered as an important adjunct therapy to statins and diet in
lowering LDL cholesterol."
study subjects had type 2 diabetes for at least one year. They exhibited
poorly controlled blood glucose levels, as measured by fasting blood
glucose (FBG) above 200 mg/dL and elevated glycosylated hemoglobin
(HbA1c) above 7%, despite taking anti-diabetic medications for at
least six months. Subjects were divided into two groups to randomly
receive either Diachrome or placebo daily, while continuing
their prescription medications. The 30-day measurements also showed
a decrease in average triglyceride levels, although it was not statistically
Diachrome continues to show effectiveness in improving blood
glucose levels for people with type 2 diabetes, evidence is also
building as to positive effects on coronary risk factors," explains
Anne Daly, MS, RD, BC-ADM, CDE, author and expert in diabetes care
and education. "These data indicate the need for further study into
the potential for Diachrome to help prevent cardiovascular disease,
which is the leading cause of diabetes-related death."
21 commissioned the cohort study through Radiant Research. In addition,
the Company is collaborating with XLHealth Systems, formerly known
as Diabetex, in an ongoing clinical trial measuring blood glucose
levels as well as multiple heart disease risk factors in more than
500 people with type 2 diabetes scheduled for completion at the
end of 2004.
pleased to see these beneficial results in only 30 days that support
the potential for Diachrome as a nutritional adjunct to diabetes
therapy," said Gail Montgomery, president and CEO of Nutrition 21.
"As our research program nears completion we hope to conclusively
demonstrate that Diachrome offers a safe, convenient and effective
means of managing multiple risk factors associated with diabetes
and lowering the cost of patient care."
is a patented nutritional supplement composed of Chromax® chromium
picolinate and biotin. These two ingredients are both Generally
Recognized as Safe (GRAS) for use as ingredients in food and supplements.
Research indicates that chromium, in the form of chromium picolinate,
enhances blood sugar control in people with insulin resistance and
type 2 diabetes. Biotin, also known as vitamin H, has independently
demonstrated glucose and lipid-reducing effects. Chromium is an
essential mineral that is required for proper insulin function and
21 is a nutrition bioscience company, which develops and markets
nutritional products, with health benefits substantiated by clinical
research. The Company markets Chromax®, the leading brand of
chromium, and holds 35 patents for nutrition products, 22 for chromium
compounds and their uses. For more information, consumers and health
professionals may call 1-866-DIACHROME or visit the websites shown
21, Inc. (www.nutrition21.com,